

Degradable Fe₃O₄-Based Nanocomposite for Cascade Reaction-Enhanced Anti-Tumor Therapy

Yang Wang,^{a,*} Xun Li,^{b,1} Yuan Fang,^a Jianhua Wang,^a Danhong Yan,^a Baisong Chang^{b,*}




Fig. S1 FTIR spectra of Fe₃O₄-PLGA, PLGA and F127




Fig. S2 TEM images (a-c) and AFM images (d-f) of Fe₃O₄-PLGA nanocomposites with different PLGA/Fe₃O₄ mass ratio (2:1(a, d), 3:1(b, e), 4:1(c, f))




Fig. S3 VSM for Fe_3O_4 -OA and Fe_3O_4 -PLGA




Fig. S4 Time-course absorbance of Fe_3O_4 -PLGA-H₂O₂-TMB systems upon the addition of varied concentrations of H₂O₂




Fig. S5 EPR spectra of •OH trapped by DMPO under different conditions: (1) control, (2) Fe₃O₄-PLGA nanocomposite with 10 mM H₂O₂ at pH 5.0, (3) Fe₃O₄/GOx-PLGA nanocomposite with 5 mM β-D-glucose at pH 5.0




Fig. S6 Fluorescence images of viable and dead cell distributions after separate incubation with Fe₃O₄-PLGA and Fe₃O₄/GOx-PLGA nanocomposites under neutral (pH = 7.4) at varied concentrations for 6 h




Fig. S7 CLSM images of HeLa cells after co-incubation with Fe₃O₄/GOx-PLGA nanocomposite under neutral (pH = 7.4) conditions at varied concentrations for 6 h




Fig. S8 CLSM images of HeLa cells after co-incubation with Fe₃O₄/GOx-PLGA nanocomposite under acidic (pH = 6.0) conditions at varied concentrations for 6 h